M&A Deal Summary |
|
|---|---|
| Date | 2016-11-30 |
| Target | G7 Therapeutics AG |
| Sector | Life Science |
| Buyer(s) | Heptares Therapeutics |
| Deal Type | Add-on Acquisition |
| Deal Value | 12M CHF |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
Heptares Therapeutics Ltd. is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Its proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |